These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 16123497)

  • 1. Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Jacobsen SL; Köhler-Forsberg O; Rohde C
    Schizophr Res; 2024 Aug; 270():231-234. PubMed ID: 38936114
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Ceriello A; Prattichizzo F; Berra CC; Caballero AE
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894-895. PubMed ID: 37996193
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes].
    Prasad K
    Ceylon Med J; 2022 Sep; 67(3):71-74. PubMed ID: 37930131
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
    Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study.
    Nam SH; Kim M; Kim YJ; Ahn SM; Hong S; Lee CK; Yoo B; Oh JS; Kim YG
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of inflammatory bowel disease treatments on patients with diabetes mellitus.
    Bower JAJ; O'Flynn L; Kakad R; Aldulaimi D
    World J Diabetes; 2021 Aug; 12(8):1248-1254. PubMed ID: 34512890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
    Dal Bello G; Gisondi P; Idolazzi L; Girolomoni G
    Rheumatol Ther; 2020 Jun; 7(2):271-285. PubMed ID: 32306243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis.
    Wood PR; Manning E; Baker JF; England B; Davis L; Cannon GW; Mikuls TR; Caplan L
    World J Diabetes; 2018 Feb; 9(2):53-58. PubMed ID: 29531640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.
    Pilla SJ; Quan AQ; Germain-Lee EL; Hellmann DB; Mathioudakis NN
    Curr Diab Rep; 2016 Oct; 16(10):91. PubMed ID: 27525682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom.
    Havas S
    Arch Intern Med; 2009 Jan; 169(2):150-4. PubMed ID: 19171811
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering effects of sulfasalazine in type 2 diabetes.
    Haas RM; Li P; Chu JW
    Diabetes Care; 2005 Sep; 28(9):2238-9. PubMed ID: 16123497
    [No Abstract]   [Full Text] [Related]  

  • 14. Intensified glucose lowering in type 2 diabetes: don't throw the baby out with the bathwater.
    DeVries JH
    Diabetologia; 2011 Mar; 54(3):705-6; author reply 707-8. PubMed ID: 21127831
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal.
    Czupryniak L; Szymańska-Garbacz E; Pawłowski M; Saryusz-Wolska M; Loba J
    Diabetologia; 2011 Mar; 54(3):701-2; author reply 707-8. PubMed ID: 21161162
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.